



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/638,215	08/07/2003	Rebecca Gottlieb	047711-0316	3315

23392 7590 07/08/2009  
FOLEY & LARDNER  
555 South Flower Street  
SUITE 3500  
LOS ANGELES, CA 90071-2411

EXAMINER
----------

GRAY, PHILLIP A

ART UNIT	PAPER NUMBER
----------	--------------

3767

MAIL DATE	DELIVERY MODE
-----------	---------------

07/08/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/638,215	<b>Applicant(s)</b> GOTTLIEB ET AL.	
	<b>Examiner</b> Phillip Gray	<b>Art Unit</b> 3767	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 19 March 2009.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-23 and 49-62 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-23 and 49-62 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

This Office Action is in response to applicant's communication of 3/19/2009.  
Currently amended claims 1-23 and 49-62 are pending and rejected.

#### ***Response to Arguments***

Applicant's arguments filed 3/19/2009 have been fully considered but they are not persuasive. In explanation of the newly added claims 55-62, examiner is considering stent proximal end (near 29 to 28) as in figure 3, sensor 27, by distal end (area from 28 to 11 numerals). Concerning the outlet/stent/sensing arrangement see figure 3 and outlet unnumbered/stent 28/sensing element 27.

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-11,14-23 and 49-62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barry (U.S. Patent Application Number US2002/0077592 A1) in view of Tu et al. (U.S. Patent Number 6,053,913). Barry discloses a replenishable stent and drug delivery system (see figures 1-16 and paragraphs at [0002]-[0048] generally, specific embodiments at [0067]-[0097]). Barry discloses a method for mitigating restenosis at a trauma site (where a stent is located) within the vasculature comprising: positioning a balloon catheter adjacent, interior to the stent, before or after a stent procedure, at a trauma site; and extending a sensor through a lumen in the catheter and through the stent (see element 255 and figures 11,13-15); and delivering a restenosis mitigating drug through apertures in the balloon catheter, upstream to the trauma site. The Barry sensor (255) sensing element is located on one side of and is spaced from the stent (as in figure 13) and the outlet of the catheter is located on the opposite side of the stent at which the sensing element is located, so that the stent is between the outlet and sensor.

Barry discloses the balloon catheter abuts a wall of the vasculature at the trauma site after the balloon catheter is expanded and also adjusting the flow rate and dispersal pattern of the restenosis mitigating drug. Barry further discloses using a restenosis mitigating agent or drug, which would include the use of insulin, nitric oxide, antibody, steroid , interleukin, blood thinner, ect. (see paragraph [0075]).

Barry discloses the claimed invention except for the step of extending the sensor “through the stent to a position located outside of the catheter and outside of the stent” (as added in the applicant’s most recent amendments). Tu et al. teaches that it is known to use the step of extending the sensor through the stent to a position located outside of the catheter and outside of the stent (see Tu figure 3) as set forth in paragraphs beginning at column 5 lines 20-27, to provide the surgeon a measurement of tissue temperature. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method as taught by Barry with the step of extending the sensor “through the stent to a position located outside of the catheter and outside of the stent” as taught by Tu, since such a modification would provide the method with the step of extending the sensor “through the stent to a position located outside of the catheter and outside of the stent” for providing the surgeon a measurement of tissue temperature.

Concerning claims 55-62, examiner is considering stent proximal end (near 29 to 28) as in figure 3, sensor 27, by distal end (area from 28 to 11 numerals). Concerning the outlet/stent/sensing arrangement see figure 3 and outlet unnumbered/stent 28/sensing element 27.

Claims 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view Tu in further view of Silver (U.S. Patent Number 6,442,413). Silver discloses an implantable glucose sensor that can be used for implantation in a blood vessel.

Barry in view Adair discloses the claimed invention of a method for mitigating restenosis at a trauma site at which a stent and catheter and sensor are located except for the sensor sensing analyte or glucose. Silver teaches that it is known to use a method where the delivery of the restenosis mitigating drug is modified in response to the sensing of analyte by a sensor as set forth beginning at paragraphs at column 6 line 65 to provide a means to monitor and control glucose levels in the environment. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method as taught by Barry in view Adair with delivery of the restenosis mitigating drug is modified in response to the sensing of analyte by a sensor as taught by Silver since such a modification would provide the method to treat restenosis with a sensor for sensing analyte for providing a means to monitor and control glucose levels in the environment.

Claims 4, 19-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view Tu. Barry in view Tu discloses the claimed invention except for the specific mention of using the specific drugs. Examiner believes these drugs to be implicitly stated in the Barry in view Tu reference and thus an appropriate rejection. However if not directly disclosed in Barry in view Tu, they are obvious. It would have been obvious to one having ordinary skill in the art at the time the invention was made to use a restenosis mitigating drug of insulin, nitric oxide, antibody, steroid , interleukin, blood thinner, ect, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a

matter of obvious design choice. *In re Leshin*, 227 F.2d 197, 125 USPQ 416 (CCPA 1960).

### **Conclusion**

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gray whose telephone number is (571)272-7180. The examiner can normally be reached on Monday through Friday, 8:30 a.m. to 4:30 p.m. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Phillip Gray/  
Examiner, Art Unit 3767  
/Kevin C. Sirmons/  
Supervisory Patent Examiner, Art Unit 3767